Muscle-invasive Urothelial Cancer: Association of Mutational Status with Metastatic Pattern and Survival.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 32228295.
- Also identified by DOI 10.1148/radiol.2020191770.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Background Muscle-invasive urothelial cancer (MIUC) is characterized by substantial genetic heterogeneity and high mutational frequency. Correlation between frequently mutated genes with clinical behavior has been recently demonstrated. Nonetheless, correlation between mutational status of MIUC and metastatic pattern is unknown. Purpose To investigate the association of mutational status of MIUC with metastatic pattern, metastasis-free survival (MFS), and overall survival (OS). Materials and Methods This single-center retrospective study evaluated consecutive patients with biopsy-proven MIUC who underwent serial cross-sectional imaging (CT, MRI, or fluorine 18 fluorodeoxyglucose PET/CT) between April 2010 and December 2018. Mutational status was correlated with location of metastases using the χ<sup>2</sup> or Fisher exact test. Mutational status and metastatic pattern were correlated with MFS and OS using univariable Cox proportional hazard models. High-risk (presence of <i>TP53</i>, <i>RB1</i>, or <i>KDM6A</i> mutation) and low-risk (presence of <i>ARID1A</i>, <i>FGFR3</i>, <i>PIK3CA</i>, <i>STAG2</i>, and/or <i>TSC1</i> mutation and absence of <i>TP53</i>, <i>RB1</i>, or <i>KDM6A</i> mutation) groups were determined according to existing literature and were correlated with MFS and OS by using multivariable Cox proportional hazard models. Results One hundred three patients (mean age, 72 years ± 11 [standard deviation]; 81 men) were evaluated. Seventeen of 103 (16%) patients had metastatic disease at diagnosis; 38 of 103 (37%) developed metastatic disease at a median of 5.9 months (interquartile range, 0.8-28 months). <i>TP53</i> mutation (seen in 58 of 103 patients, 56%) was associated with lymphadenopathy (relative risk [RR]: 1.7; 95% confidence interval [CI]: 1.2, 2.4; <i>P</i> = .002) and osseous metastases (RR: 1.9; 95% CI: 1.6, 2.3; <i>P</i> = .02); <i>RB1</i> mutation (seen in 19 of 103 patients, 18.4%) was associated with peritoneal carcinomatosis (RR: 5.9; 95% CI: 3.8, 9.2; <i>P</i> = .03). <i>ARID1A</i> mutation was associated with greater OS (hazard ratio [HR]: 3.1; 95% CI: 1.2, 10; <i>P</i> = .01). At multivariable Cox analysis, the high-risk group (<i>TP53</i>, <i>RB1</i>, and/or <i>KDM6A</i> mutations) was independently associated with shorter MFS (HR: 3.5, 95% CI: 1.3, 12; <i>P</i> = .009) and shorter OS (HR: 3.1; 95% CI: 1.2, 10; <i>P</i> = .02). Conclusion Mutational status of muscle-invasive urothelial cancer has implications on metastatic pattern, metastasis-free survival, and overall survival. © RSNA, 2020 <i>Online supplemental material is available for this article.</i> See also the editorial by Choyke in this issue.
Medical subject headings
- Carcinoma, Transitional Cell
- Histone Demethylases
- Kidney Neoplasms
- Retinoblastoma Binding Proteins
- Tumor Suppressor Protein p53
- Ubiquitin-Protein Ligases